作者
Auddie M Sweis, Tran B Locke, Kevin I Ig-Izevbekhai, Theodore C Lin, Ankur Kumar, Jennifer E Douglas, Andrew M Corr, Alyssa M Civantos, Siddhant H Tripathi, David W Kennedy, Michael A Kohanski, James N Palmer, Nithin D Adappa, John V Bosso
发表日期
2021/3
期刊
Allergy and Asthma Proceedings
卷号
42
期号
2
页码范围
136
出版商
OceanSide Publications
简介
Background:
Aspirin therapy and/or type 2 (T2) biologics are used in the management of aspirin-exacerbated respiratory disease (AERD).
Objective:
To identify the number of patients with AERD who tolerated aspirin therapy, yet due to persistent symptoms, incorporated T2 biologic management.
Methods:
A retrospective review was performed between July 2016 and June 2019. Patients with AERD and who underwent endoscopic sinus surgery (ESS), aspirin desensitization (AD), and at least 6 months of aspirin therapy (ATAD) after AD, and who remained biologic-naive up through this timepoint were included in the study. Introduction of a T2 biologic while on ATAD was the primary outcome. The secondary outcome was a change in a validated patient-reported outcome measure for chronic rhinosinusitis score between the postoperative predesensitization timepoint, and the 6-month postdesensitization timepoint …
学术搜索中的文章
AM Sweis, TB Locke, KI Ig-Izevbekhai, TC Lin, A Kumar… - Allergy and Asthma Proceedings, 2021